SCHEMBL17633464

SCHEMBL17633464

CCC(Nc1ncnc(N)c1C#N)c1cc2ncc(Cl)n2nc1-c1cccc(F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 20/20 1.00
PIK3R2 O00459 14/20 0.83
PIK3CG P48736 13/20 0.81
PIK3CB P42338 1/20 0.66
PIK3R1 P27986 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17633462 1.00 PIK3CD (1.00) PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1
SCHEMBL17640766 1.00 PIK3CD (1.00) PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1
SCHEMBL19307667 0.91 PIK3CD (1.00) PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1
SCHEMBL19307677 0.91 PIK3CD (1.00) PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1
SCHEMBL19307666 0.91 PIK3CD (1.00) PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1
SCHEMBL20964155 0.90 PIK3CD (1.00) PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1
SCHEMBL17640653 0.90 PIK3CD (1.00) PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1
SCHEMBL17640762 0.86 PIK3CD (1.00) PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1
SCHEMBL19307652 0.84 PIK3CD (0.72) PIK3CDPIK3R2PIK3CG
SCHEMBL19307651 0.84 PIK3CD (0.72) PIK3CDPIK3R2PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10611777-B2 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2020-04-07 US disclosed
US-10611777-B2 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2020-04-07 US disclosed
US-20190127391-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LTD (CN) 2019-05-02 US disclosed
US-20190127391-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LTD (CN) 2019-05-02 US disclosed
US-10208066-B2 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2019-02-19 US disclosed
US-10208066-B2 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2019-02-19 US disclosed
US-20170253618-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2017-09-07 US disclosed
US-20170253618-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2017-09-07 US disclosed
EP-3197898-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE Hutchison Medipharma Limited (CN) 2017-08-02 EP disclosed
WO-2016045591-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253618-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE PIK3R5, PIK3CD, PIK3CB PIK3CD 2/4885PIK3R2 10/4885PIK3CG 9/4885
US-10208066-B2 Imidazopyridazine compounds and their use PIK3R5, PIK3CD, INPP5D PIK3CD 2/4885PIK3R2 9/4885PIK3CG 8/4885
US-20190127391-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE PIK3R5, PIK3CD, PIK3CB PIK3CD 2/4885PIK3R2 10/4885PIK3CG 9/4885
US-10611777-B2 Imidazopyridazine compounds and their use PIK3R5, PIK3CD, INPP5D PIK3CD 2/4885PIK3R2 9/4885PIK3CG 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.